On Tuesday, Following Stocks were among the “Top Losers” of U.S. Stock Market: Synta Pharmaceuticals, (NASDAQ:SNTA), Raptor Pharmaceuticals, (NASDAQ:RPTP), BG Medicine, (NASDAQ:BGMD), Ohr Pharmaceutical, (NASDAQ:OHRP)
Synta Pharmaceuticals, (NASDAQ:SNTA), with shares declined -16.74%, closed at $1.94, hitting new 52-week low of $1.85.
Raptor Pharmaceuticals, (NASDAQ:RPTP), with shares dropped -9.72%, settled at $10.87.
BG Medicine, (NASDAQ:BGMD), with shares dipped -14.74%, and closed at $0.81.
Ohr Pharmaceutical, (NASDAQ:OHRP), plummeted -9.61%, and closed at $2.54, hitting new 52-week low of $2.51.
Latest NEWS regarding these Stocks are depicted underneath:
Synta Pharmaceuticals Corp. (NASDAQ:SNTA)
Synta Pharmaceuticals Corp. (SNTA), declared that it has priced an underwritten public offering of 22,000,000 shares of its ordinary stock at a price to the public of $1.75 per share. Gross proceeds to Synta are predictable to be about $38.5 million, before deducting the underwriting discounts and commissions and estimated offering expenses payable by Synta. The offering is predictable to close on or about April 6, 2015, subject to satisfaction of customary closing conditions. Synta has granted the underwriters a thirty (30) day option to purchase up to 3,300,000 additional shares.
Jefferies LLC and Cowen and Corporation, LLC are acting as joint book-running managers for the offering, and JMP Securities LLC and Roth Capital Partners, LLC are acting as co-managers for the offering.
Synta Pharmaceuticals Corp., a biopharmaceutical corporation, focuses on the research, development, and commercialization of novel oncology medicines for cancer patients. Its lead oncology drug candidate comprises ganetespib, an Hsp90 inhibitor, which is in Phase III clinical trial for the treatment of non-small cell lung cancer; in Phase II clinical trial for patients with hormone receptor positive metastatic breast cancer; in Phase I clinical trial for the treatment of HER2 positive patients with metastatic breast cancer; in Phase II/III clinical trial for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome; in Phase I/II trial of paclitaxel in combination with ganetespib in patients with platinum-resistant ovarian cancer; and in Phase I/II trial in combination with the mTOR inhibitor sirolimus in patients with refractory sarcoma.
Raptor Pharmaceuticals Corp. (NASDAQ:RPTP)
Raptor Pharmaceuticals Corp. (RPTP), declared that it has commenced an underwritten public offering of $75 million of shares of its ordinary stock. In addition, the corporation is predictable to grant the underwriters of the offering an option for a period of 30 days to purchase up to an additional 15 percent of the number of shares of ordinary stock sold in the offering at the public offering price, less the underwriting discounts and commissions. All of the shares are being offered by the corporation. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be accomplished.
Citigroup, Leerink Partners and Cowen and Corporation are acting as lead joint book-running managers for the offering. JMP Securities is acting as lead manager and Janney Montgomery Scott LLC is acting as a co-manager for the offering.
Raptor Pharmaceutical Corp., a biopharmaceutical corporation, focuses on developing and commercializing life-altering therapeutics that treat debilitating and often fatal diseases.
BG Medicine, Inc. (NASDAQ:BGMD)
BG Medicine, Inc. (BGMD), stated financial results for the three months and year ended December 31, 2014.
The Corporation stated net loss for the full year of $8.1 million, a 49% improvement from the $15.8 million net loss stated in 2013, on total proceeds of $2.8 million as compared to total proceeds of $4.1 million in 2013. Operating expenses for 2014 declined by 46% from the preceding year. Net loss per share at year end of 2014 was $0.25 as contrast to $0.58 in 2013. Operating cash burn reduced by $7.1 million, a 47% decrease, to $8.2 million contrast to $15.3 million in 2013.
“In 2014, we continued to build the case for galectin-3 while managing our operating expenses aggressively and reducing our operating cash burn,” said Paul R. Sohmer, M.D., President and Chief Executive Officer of BG Medicine.
BG Medicine, Inc., a diagnostics corporation, develops and commercializes novel cardiovascular diagnostic tests to address unmet medical needs in the United States.
Ohr Pharmaceutical, Inc. (NASDAQ:OHRP)
Ohr Pharmaceutical, Inc. (OHRP), stated disappointing top-line results from an exploratory phase II study (INFLUENCE) evaluating OHR-102 (0.2% squalamine lactate ophthalmic solution) combination therapy for the treatment of patients suffering from the wet form of age-related macular degeneration (wet-AMD).
In the intent-to-treat (ITT-LOCF) population with classic containing choroidal neovascularization (CNV) (OHR-102 n=38, Lucentis(R) monotherapy n=32), 42% of the patients receiving OHR-102 achieved a >=3 line gain at nine months, as contrast to 28% in the Lucentis monotherapy group. Less of a benefit was seen in the overall population (classic containing and occult only CNV lesions). The classic containing CNV population represents about two thirds of the total wet-AMD population. The positive effect on visual acuity in classic CNV was seen early in the course of treatment and continued to raise through the end of the study, supporting the planned Phase III development program.
In patients with classic CNV (ITT-LOCF), mean gains in visual acuity were +10.5 letters for the OHR-102 combination arm and +5.4 letters with Lucentis monotherapy, a clinically meaningful benefit of +5.1 letters. The mean number of injections between the treatment arms, the primary endpoint of the study, was not meaningfully different. Detailed data will be presented at the forthcoming Association for Research in Vision and Ophthalmology (ARVO) scientific meeting, which will take place May 3rd — 7th.
OHR Pharmaceutical, Inc., a pharmaceutical company, focuses on the development of novel therapeutics and delivery technologies for the treatment of ocular disease. Its lead clinical program is OHR-102 eye drops, a novel therapeutic product, which could provide a non-invasive therapy to improve vision outcomes.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
